A61K 38/58
From leeches
Official title: from leeches, e.g. hirudin, eglin
A61K38/58 (From leeches) appears on 66 US grants and 112 published applications in this corpus.
Search patents in A61K- Granted patents
- 66
- Published applications
- 112
- Assignees
- 89
- Inventors
- 241
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 3 | 0 |
| 1999 | 4 | 0 |
| 2000 | 1 | 0 |
| 2001 | 4 | 1 |
| 2002 | 6 | 0 |
| 2003 | 1 | 2 |
| 2004 | 0 | 5 |
| 2005 | 0 | 5 |
| 2006 | 1 | 5 |
| 2007 | 0 | 7 |
| 2008 | 1 | 6 |
| 2009 | 2 | 4 |
| 2010 | 4 | 5 |
| 2011 | 1 | 4 |
| 2012 | 0 | 5 |
| 2013 | 2 | 9 |
| 2014 | 0 | 3 |
| 2015 | 1 | 5 |
| 2016 | 2 | 6 |
| 2017 | 3 | 6 |
| 2018 | 5 | 0 |
| 2019 | 2 | 4 |
| 2020 | 1 | 2 |
| 2021 | 3 | 1 |
| 2022 | 0 | 7 |
| 2023 | 0 | 11 |
| 2024 | 4 | 3 |
| 2025 | 2 | 4 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient31 Mar 2026US 12,589,095 B2Primo Pharmatech LLC
- Ready-to-use bivalirudin compositions18 Nov 2025US 12,472,224 B2Maia Pharmaceuticals, Inc.
- Peptide directed protein knockdown30 Sep 2025US 12,428,456 B2The University of British Columbia
- Ready-to-use bivalirudin compositions28 May 2024US 11,992,514 B2Maia Pharmaceuticals, Inc.
- Ready-to-use bivalirudin compositions5 Mar 2024US 11,918,622 B2Maia Pharmaceuticals, Inc.
- mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal7 May 2026US 2026/0124188 A1Orphelion AB
- Compositions and methods for treatment of virus-induced airway fibrosis8 Jan 2026US 2026/0007597 A1The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- Hirudin formula composition with anticoagulant and hypolipidemic effects and preparation method thereof4 Dec 2025US 2025/0367272 A1Nano Biology Limited
- Methods of treating or preventing stent thrombosis17 Jul 2025US 2025/0228948 A1Chiesi Farmaceutici S.P. A.
- Thrombin and fibrinogen as targets for atopic dermatitis diagnosis and treatment5 Jun 2025US 2025/0177502 A1Children's Hospital Medical Center
Most cited
By later US patents
- Localized use of nitric oxide-adducts to prevent internal tissue damage146US 6,087,479 ANitroMed, Inc. · 2000
- Localized use of nitric oxide-adducts to prevent internal tissue damage74US 6,471,978 B1NitroMed, Inc. · 2002
- Localized use of nitric oxide adducts to prevent internal tissue damage53US 6,174,539 B1NitroMed, Inc. · 2001
- Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.45US 5,510,330 ABoehringer Mannheim GmbH · 1996
- Cardiovascular disease treatment and prevention41US 9,339,457 B2Transdermal Biotechnology, Inc. · 2016